{"id":858860,"date":"2025-06-10T07:09:56","date_gmt":"2025-06-10T11:09:56","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/gyre-therapeutics-announces-first-dosing-in-phase-1-trial-of-f230-for-pulmonary-arterial-hypertension-in-china\/"},"modified":"2025-06-10T07:09:56","modified_gmt":"2025-06-10T11:09:56","slug":"gyre-therapeutics-announces-first-dosing-in-phase-1-trial-of-f230-for-pulmonary-arterial-hypertension-in-china","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/gyre-therapeutics-announces-first-dosing-in-phase-1-trial-of-f230-for-pulmonary-arterial-hypertension-in-china\/","title":{"rendered":"Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SAN DIEGO, June  10, 2025  (GLOBE NEWSWIRE) &#8212; Gyre Therapeutics (\u201cGyre\u201d) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced that the first volunteer has been successfully dosed in a Phase 1 clinical trial evaluating F230, a novel endothelin A (\u201cETA\u201d) receptor antagonist, for the treatment of pulmonary arterial hypertension (\u201cPAH\u201d).<\/p>\n<p>This milestone marks Gyre\u2019s entry into the PAH field, a rare, progressive, and high-mortality cardiovascular condition with limited treatment options. PAH is recognized in China\u2019s National Rare Disease Catalog, underscoring its significance in public health. According to Frost &amp; Sullivan, China\u2019s PAH market was valued at $370 million in 2023 and is projected to grow to $480 million by 2031.<\/p>\n<p>F230, originally discovered by Eisai Co., Ltd. and exclusively licensed by GNI Group Ltd. to Gyre, is a fully synthetic small molecule designed to selectively block the ETA receptor. By targeting this pathway, F230 is designed to reduce pulmonary vascular remodeling and lower pulmonary pressure, key contributors to PAH progression.<\/p>\n<p>The Phase 1 trial is designed to evaluate safety, tolerability, and pharmacokinetics in healthy volunteers. The trial represents the latest expansion of Gyre\u2019s fibrosis-first strategy beyond the liver, leveraging a robust clinical development platform and commercial infrastructure in China.<\/p>\n<p>F230 joins Gyre\u2019s pipeline alongside lead candidate Hydronidone (F351), which met the primary endpoint in a pivotal Phase 3 trial for CHB-fibrosis. A New Drug Application (\u201cNDA\u201d) submission to China\u2019s National Medical Products Administration (\u201cNMPA\u201d) is planned for the third quarter of 2025, and a pre-IND meeting with the U.S. Food and Drug Administration is being planned for an expected Phase 2 trial in metabolic dysfunction-associated steatohepatitis (\u201cMASH\u201d) fibrosis.<\/p>\n<p>About Gyre Therapeutics<\/p>\n<p>Gyre Therapeutics is a biopharmaceutical company headquartered in San Diego, CA, primarily focused on the development and commercialization of Hydronidone for liver fibrosis, including MASH, in the U.S. Gyre\u2019s strategy builds on its experience in mechanistic studies using MASH rodent models and clinical studies in CHB-induced liver fibrosis. In the People\u2019s Republic of China, Gyre is advancing a broad pipeline through its indirect controlling interest in Gyre Pharmaceuticals, including therapeutic expansions of ETUARY, and development programs for F573, F528, and F230.<\/p>\n<p>Forward-Looking Statements<\/p>\n<p>This press release contains \u201cforward-looking statements\u201d within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, are forward-looking statements, including statements concerning the expectations regarding Gyre\u2019s research and development efforts and timing of expected clinical trials, including an NDA submission to the NMPA for F351, the expected clinical benefits of F230 and expectations regarding interactions with regulators. In some cases, you can identify forward-looking statements by terms such as \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cobjective,\u201d \u201cintend,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201ccan,\u201d \u201cwould,\u201d \u201cexpect,\u201d \u201cbelieve,\u201d \u201cdesign,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cpotential,\u201d \u201cplan\u201d or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation: Gyre\u2019s ability to execute on its clinical development strategies; positive results from a clinical trial may not necessarily be predictive of the results of future or ongoing clinical trials; the timing or likelihood of regulatory filings and approvals; competition from competing products; the impact of general economic, health, industrial or political conditions in the United States or internationally; the sufficiency of Gyre\u2019s capital resources and its ability to raise additional capital. Additional risks and factors are identified under \u201cRisk Factors\u201d in Gyre\u2019s Annual Report on Form 10-K for the year ended December 31, 2024 filed on March 17, 2025 and in other filings Gyre may make with the SEC.<\/p>\n<p>Gyre expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.<\/p>\n<p>Investor Contact:<br \/>David Zhang<br \/>Gyre Therapeutics<br \/>david.zhang@gyretx.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NTg5NSM2OTgwOTYwIzIwMTkzMzY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OTZmZGVmYjAtYjBjZS00YzcwLTk1NjUtMzhjNmFiZWQwNTM1LTEwMzA5MDktMjAyNS0wNi0xMC1lbg==\/tiny\/Gyre-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, June 10, 2025 (GLOBE NEWSWIRE) &#8212; Gyre Therapeutics (\u201cGyre\u201d) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced that the first volunteer has been successfully dosed in a Phase 1 clinical trial evaluating F230, a novel endothelin A (\u201cETA\u201d) receptor antagonist, for the treatment of pulmonary arterial hypertension (\u201cPAH\u201d). This milestone marks Gyre\u2019s entry into the PAH field, a rare, progressive, and high-mortality cardiovascular condition with limited treatment options. PAH is recognized in China\u2019s National Rare Disease Catalog, underscoring its significance in public health. According to Frost &amp; Sullivan, China\u2019s PAH market was valued at $370 million in 2023 and is projected to grow to $480 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/gyre-therapeutics-announces-first-dosing-in-phase-1-trial-of-f230-for-pulmonary-arterial-hypertension-in-china\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-858860","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/gyre-therapeutics-announces-first-dosing-in-phase-1-trial-of-f230-for-pulmonary-arterial-hypertension-in-china\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, June 10, 2025 (GLOBE NEWSWIRE) &#8212; Gyre Therapeutics (\u201cGyre\u201d) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced that the first volunteer has been successfully dosed in a Phase 1 clinical trial evaluating F230, a novel endothelin A (\u201cETA\u201d) receptor antagonist, for the treatment of pulmonary arterial hypertension (\u201cPAH\u201d). This milestone marks Gyre\u2019s entry into the PAH field, a rare, progressive, and high-mortality cardiovascular condition with limited treatment options. PAH is recognized in China\u2019s National Rare Disease Catalog, underscoring its significance in public health. According to Frost &amp; Sullivan, China\u2019s PAH market was valued at $370 million in 2023 and is projected to grow to $480 &hellip; Continue reading &quot;Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/gyre-therapeutics-announces-first-dosing-in-phase-1-trial-of-f230-for-pulmonary-arterial-hypertension-in-china\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-10T11:09:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NTg5NSM2OTgwOTYwIzIwMTkzMzY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gyre-therapeutics-announces-first-dosing-in-phase-1-trial-of-f230-for-pulmonary-arterial-hypertension-in-china\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gyre-therapeutics-announces-first-dosing-in-phase-1-trial-of-f230-for-pulmonary-arterial-hypertension-in-china\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China\",\"datePublished\":\"2025-06-10T11:09:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gyre-therapeutics-announces-first-dosing-in-phase-1-trial-of-f230-for-pulmonary-arterial-hypertension-in-china\\\/\"},\"wordCount\":735,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gyre-therapeutics-announces-first-dosing-in-phase-1-trial-of-f230-for-pulmonary-arterial-hypertension-in-china\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2NTg5NSM2OTgwOTYwIzIwMTkzMzY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gyre-therapeutics-announces-first-dosing-in-phase-1-trial-of-f230-for-pulmonary-arterial-hypertension-in-china\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gyre-therapeutics-announces-first-dosing-in-phase-1-trial-of-f230-for-pulmonary-arterial-hypertension-in-china\\\/\",\"name\":\"Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gyre-therapeutics-announces-first-dosing-in-phase-1-trial-of-f230-for-pulmonary-arterial-hypertension-in-china\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gyre-therapeutics-announces-first-dosing-in-phase-1-trial-of-f230-for-pulmonary-arterial-hypertension-in-china\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2NTg5NSM2OTgwOTYwIzIwMTkzMzY=\",\"datePublished\":\"2025-06-10T11:09:56+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gyre-therapeutics-announces-first-dosing-in-phase-1-trial-of-f230-for-pulmonary-arterial-hypertension-in-china\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gyre-therapeutics-announces-first-dosing-in-phase-1-trial-of-f230-for-pulmonary-arterial-hypertension-in-china\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gyre-therapeutics-announces-first-dosing-in-phase-1-trial-of-f230-for-pulmonary-arterial-hypertension-in-china\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2NTg5NSM2OTgwOTYwIzIwMTkzMzY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2NTg5NSM2OTgwOTYwIzIwMTkzMzY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gyre-therapeutics-announces-first-dosing-in-phase-1-trial-of-f230-for-pulmonary-arterial-hypertension-in-china\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/gyre-therapeutics-announces-first-dosing-in-phase-1-trial-of-f230-for-pulmonary-arterial-hypertension-in-china\/","og_locale":"en_US","og_type":"article","og_title":"Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China - Market Newsdesk","og_description":"SAN DIEGO, June 10, 2025 (GLOBE NEWSWIRE) &#8212; Gyre Therapeutics (\u201cGyre\u201d) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced that the first volunteer has been successfully dosed in a Phase 1 clinical trial evaluating F230, a novel endothelin A (\u201cETA\u201d) receptor antagonist, for the treatment of pulmonary arterial hypertension (\u201cPAH\u201d). This milestone marks Gyre\u2019s entry into the PAH field, a rare, progressive, and high-mortality cardiovascular condition with limited treatment options. PAH is recognized in China\u2019s National Rare Disease Catalog, underscoring its significance in public health. According to Frost &amp; Sullivan, China\u2019s PAH market was valued at $370 million in 2023 and is projected to grow to $480 &hellip; Continue reading \"Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/gyre-therapeutics-announces-first-dosing-in-phase-1-trial-of-f230-for-pulmonary-arterial-hypertension-in-china\/","og_site_name":"Market Newsdesk","article_published_time":"2025-06-10T11:09:56+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NTg5NSM2OTgwOTYwIzIwMTkzMzY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gyre-therapeutics-announces-first-dosing-in-phase-1-trial-of-f230-for-pulmonary-arterial-hypertension-in-china\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gyre-therapeutics-announces-first-dosing-in-phase-1-trial-of-f230-for-pulmonary-arterial-hypertension-in-china\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China","datePublished":"2025-06-10T11:09:56+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gyre-therapeutics-announces-first-dosing-in-phase-1-trial-of-f230-for-pulmonary-arterial-hypertension-in-china\/"},"wordCount":735,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gyre-therapeutics-announces-first-dosing-in-phase-1-trial-of-f230-for-pulmonary-arterial-hypertension-in-china\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NTg5NSM2OTgwOTYwIzIwMTkzMzY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gyre-therapeutics-announces-first-dosing-in-phase-1-trial-of-f230-for-pulmonary-arterial-hypertension-in-china\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/gyre-therapeutics-announces-first-dosing-in-phase-1-trial-of-f230-for-pulmonary-arterial-hypertension-in-china\/","name":"Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gyre-therapeutics-announces-first-dosing-in-phase-1-trial-of-f230-for-pulmonary-arterial-hypertension-in-china\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gyre-therapeutics-announces-first-dosing-in-phase-1-trial-of-f230-for-pulmonary-arterial-hypertension-in-china\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NTg5NSM2OTgwOTYwIzIwMTkzMzY=","datePublished":"2025-06-10T11:09:56+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gyre-therapeutics-announces-first-dosing-in-phase-1-trial-of-f230-for-pulmonary-arterial-hypertension-in-china\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/gyre-therapeutics-announces-first-dosing-in-phase-1-trial-of-f230-for-pulmonary-arterial-hypertension-in-china\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gyre-therapeutics-announces-first-dosing-in-phase-1-trial-of-f230-for-pulmonary-arterial-hypertension-in-china\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NTg5NSM2OTgwOTYwIzIwMTkzMzY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NTg5NSM2OTgwOTYwIzIwMTkzMzY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gyre-therapeutics-announces-first-dosing-in-phase-1-trial-of-f230-for-pulmonary-arterial-hypertension-in-china\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/858860","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=858860"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/858860\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=858860"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=858860"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=858860"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}